Kageyama Y, Kihara K, Kamata S, Nagahama K, Yonese J, Fukuda H, Tosaka A, Nagamatsu H, Ishizaka K, Tsujii T, Kitahara S, Morita T, Oshima H
Department of Urology, Tokyo Medical and Dental University School of Medicine, Japan.
Hinyokika Kiyo. 1996 Mar;42(3):197-9.
We retrospectively reviewed pretreatment levels of serum prostate specific antigen (PSA) in 138 newly diagnosed, untreated patients with prostate adenocarcinoma to evaluate the usefulness of serum PSA levels to predict results of radionuclide bone scans. All of the 24 patients with serum PSA levels above 200 ng/ml showed positive bone scans whereas those with serum PSA levels below 10 ng/ml included only three cases (3/51, 5.1%) positive for bone metastasis. All of the three had poorly differentiated adenocarcinoma of the prostate. In conclusion, bone scans may not be necessary in the cases with serum PSA levels less than 10 ng/ml except for those with poorly differentiated adenocarcinoma.
我们回顾性分析了138例新诊断的未经治疗的前列腺腺癌患者的血清前列腺特异性抗原（PSA）预处理水平，以评估血清PSA水平预测放射性核素骨扫描结果的有效性。血清PSA水平高于200 ng/ml的24例患者骨扫描均呈阳性，而血清PSA水平低于10 ng/ml的患者中仅有3例（3/51，5.1%）骨转移呈阳性。这3例均为前列腺低分化腺癌。总之，血清PSA水平低于10 ng/ml的患者，除低分化腺癌患者外，可能无需进行骨扫描。
